What pathologic feature favors ANCA-associated glomerulonephritis over IgA nephropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pauci-Immune Immunofluorescence Pattern (Negative or Few Ig Deposits)

The pathologic feature that most strongly favors ANCA-associated glomerulonephritis over IgA nephropathy is the absence or near-absence of immunoglobulin deposits on immunofluorescence microscopy—the so-called "pauci-immune" pattern. 1

Key Distinguishing Features on Immunofluorescence

ANCA-Associated GN

  • Negative or few Ig deposits on immunofluorescence (IF) or immunohistochemistry (IHC) 1
  • This pauci-immune pattern is the hallmark feature that defines ANCA GN pathologically
  • 80-90% of patients with this pathologic pattern have serologic evidence of ANCA 1
  • When immunoglobulin deposits are present in ANCA GN, they are typically minimal and not the dominant feature

IgA Nephropathy

  • Dominant or co-dominant mesangial IgA deposits on IF 1
  • Granular pattern of IgA deposition in the mesangium
  • Often accompanied by C3 and sometimes IgG or IgM deposits
  • The presence of mesangial IgA is the defining diagnostic criterion

Additional Distinguishing Pathologic Features

Light Microscopy Patterns

While both conditions can show crescentic glomerulonephritis, ANCA GN more commonly demonstrates:

  • Fibrinoid necrosis (disruption of the GBM with fibrin exudation) 1
  • More severe necrotizing and crescentic pattern 1
  • Crescents can occur with <50% glomerular involvement in ANCA GN, whereas the term "crescentic GN" in immune-complex diseases like IgAN typically requires ≥50% involvement 1

Tubulointerstitial Injury

  • More severe acute tubulointerstitial injury is characteristic of ANCA GN compared to IgAN, even when matched for glomerular injury severity 2
  • This contributes significantly to acute kidney injury in ANCA GN independent of glomerular damage

Important Clinical Caveats

Overlap Scenarios

Be aware that rare overlap situations exist:

  • Some ANCA GN cases (22-60%) may show granular IgG and/or IgM deposition along glomerular capillaries 3
  • When IgG is present in ANCA GN, it often co-localizes with MPO, suggesting immune complex formation involving ANCA antigens 3
  • IgAN patients can occasionally be ANCA-positive (showing more severe clinical features and fibrinoid necrosis) 4
  • Both conditions can coexist in the same patient, requiring careful pathologic assessment 1

Diagnostic Algorithm

When evaluating a kidney biopsy with crescentic GN:

  1. First, examine immunofluorescence:

    • Negative/minimal Ig → Consider ANCA GN
    • Dominant mesangial IgA → Diagnose IgAN
    • Both patterns present → Report both diagnoses in order of clinical significance 1
  2. Correlate with serology:

    • Check MPO-ANCA and PR3-ANCA
    • ANCA positivity supports ANCA GN but doesn't exclude IgAN overlap
  3. Assess pattern of injury:

    • Fibrinoid necrosis strongly suggests ANCA GN 1, 4
    • Purely mesangial proliferation favors IgAN

The pauci-immune pattern on immunofluorescence remains the single most reliable pathologic feature to distinguish ANCA GN from IgAN, as it directly reflects the underlying pathogenic mechanism—vasculitis without significant immune complex deposition versus immune complex-mediated disease.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.